Swedish contract development and manufacturing company Recipharm has completed the acquisition of OnTarget Chemistry, based in Uppsala, Sweden.
OnTarget is a contract research organization with a turnover of 29 million Swedish kronor ($3.5 million), and is specialized in medicinal chemistry, offering synthesis and analytical services including rare and demanding specialties.
Recipharm will broaden its pharmaceutical development capabilities with this acquisition, including preclinical chemistry services. OnTarget’s sales in 2015 show more than 60% of total revenue outside Sweden with substantial sales in Germany, Japan and the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze